Showing results (531-540 of 554) with videos related to
Sort By:
Pageof 56
Pigment Cell & Melanoma Research|August 1, 2022
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunitiesAlcida Karz, Maya Dimitrova, Kevin Kleffman, et al.Lancet (London, England)|May 14, 2019
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trialBrian I Rini, Thomas Powles, Michael B Atkins, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trialNourhan El Ahmar, Morgan A Paul, Berkay Simsek, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2018
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJulie R Brahmer, Christina Lacchetti, Bryan J Schneider, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline UpdateBryan J Schneider, Jarushka Naidoo, Bianca D Santomasso, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2014
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinomaDavid F McDermott, Su-Chun Cheng, Sabina Signoretti, et al.Journal for Immunotherapy of Cancer|June 1, 2018
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0Ryan J Sullivan, Michael B Atkins, John M Kirkwood, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO GuidelineBianca D Santomasso, Loretta J Nastoupil, Sherry Adkins, et al.Nature Medicine|October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.The New England Journal of Medicine|June 5, 2012
Safety, activity, and immune correlates of anti-PD-1 antibody in cancerSuzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.Pageof 56